Thelansis

  Erythropoietic Protoporphyria (EPP) Market Outlook Thelansis’s “Erythropoietic Protoporphyria (EPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Erythropoietic Protoporphyria (EPP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Erythropoietic Protoporphyria (EPP) Overview Erythropoietic protoporphyria is a genetic condition that affects heme production, which leads to the overproduction of protoporphyrin, mainly in the bone marrow. This condition leads to higher levels of the heme precursor excreted in the bile. In some cases, this disorder progresses to liver disease and eventually ends with liver transplantation. Since ...

  Erythropoietic protoporphyria is a genetic condition that affects heme production, which leads to the overproduction of protoporphyrin, majorly in the bone marrow. This condition leads to higher levels of the heme precursor excreted in the bile. In some cases, this disorder progresses to liver disease and eventually ends with liver transplantation. Since the bone marrow continues to produce excessive protoporphyrin after the transplant, the condition can recur in the transplanted liver. As a result, liver transplantation, while a potential treatment, tends to be a palliative measure rather than a cure due to the risk of recurrence. EPP can result from mutations of the ferrochelatase gene (FECH). Children develop pain, redness, swelling, pruritus, and a variety of hepatobiliary complications. The 5%–10% of subjects have an X-linked variant of EPP (termed XLPP) resulting from a gain-of-function mutation of the Alas2 gene.41 Mild microcytic anemia occ...